BibbInstruments

BibbInstruments EBITDA per Share

The EBITDA per Share of BibbInstruments (BIBB.SL) as of Oct 20, 2026 is -0.36 SEK. In the previous year, EBITDA per Share was -0.40 SEK — a change of -8.96% (higher).

EBITDA per Share

-0.36SEK

YoY

-8.96%

Last updated:

EBITDA per Share of BibbInstruments is 2025 -0.36 SEK. EBITDA per Share of BibbInstruments was 2024 -0.40 SEK. It decreases by -8.96% higher compared to the previous year.

The BibbInstruments EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.54 SEK
Jan 1, 2019
-0.67 SEK
Jan 1, 2020
-0.64 SEK
Jan 1, 2021
-0.25 SEK
Jan 1, 2022
-0.28 SEK
Jan 1, 2023
-0.27 SEK
Jan 1, 2024
-0.40 SEK
Jan 1, 2025
-0.36 SEK
The BibbInstruments EBITDA per Share history
YEAREBITDA per ShareYoY
-0.36SEK-8.96%
-0.40SEK+44.39%
-0.27SEK-1.03%
-0.28SEK+9.78%
-0.25SEK-60.82%
-0.64SEK-3.89%
-0.67SEK+23.20%
-0.54SEK+91.98%
-0.28SEK-509,900.00%
0.00SEK-81.82%
0.00SEK-80.57%
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BiBBInstruments AB generates revenue through the development and sale of diagnostic instruments for early cancer detection, primarily utilizing its EndoDrill technology platform. The company markets specific products including EndoDrill GI Upper for stomach biopsies, EndoDrill GI Lower for intestinal biopsies, EndoDrill GI Lung for lung biopsies, EndoDrill Therapy for organ displacement procedures, EndoDrill Needle for breast biopsies, and EndoDrill Model X for multiple applications. These instruments are sold to hospitals with endoscopy specialist centers and surgical wards, focusing on Scandinavian countries as their primary market. The company's portfolio targets medical professionals requiring precise diagnostic tools for deep skin tissue analysis and treatment procedures. The business model centers on selling specialized biopsy instruments that enable early cancer diagnosis in various organs. EndoDrill GI Upper, GI Lower, and GI Lung are designed for gastrointestinal and respiratory tract biopsies, while EndoDrill Therapy facilitates treatment procedures involving stents and conductors. EndoDrill Needle specifically addresses breast biopsy needs, and EndoDrill Model X serves as an independent research project covering multiple anatomical areas. All products are distributed through hospital networks specializing in endoscopy and surgery. BiBBInstruments AB's revenue streams are derived from direct sales of its diagnostic instrument portfolio to healthcare institutions. The company focuses on Scandinavian countries for distribution, targeting hospitals with specialized endoscopy centers and surgical departments. The EndoDrill technology platform underpins all products, providing a unified approach to early cancer detection and treatment procedures across different medical specialties. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

EBITDA per Share of BibbInstruments is -0.36 SEK in 2025.

EBITDA per Share of BibbInstruments changed from -0.40 SEK to -0.36 SEK, representing a -8.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BibbInstruments

All Key Metrics — BibbInstruments